{"id":"dpp-4-inhibitor-sitagliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Hypoglycemia (when combined with other agents)"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DPP-4 inhibitors work by blocking the degradation of GLP-1 and GIP, incretin hormones that regulate postprandial glucose levels. By prolonging the activity of these hormones, sitagliptin enhances glucose-dependent insulin secretion and suppresses glucagon secretion, leading to improved glycemic control in type 2 diabetes without causing hypoglycemia when used as monotherapy.","oneSentence":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:56.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05768945","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":"Diabetes","enrollment":742670},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT07073768","phase":"PHASE3","title":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Khyber Medical College, Peshawar","startDate":"2025-07-01","conditions":"Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus","enrollment":126},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT06770894","phase":"PHASE3","title":"DPP4-Inhibitors and Bone Metabolism in Diabetes","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2019-09-24","conditions":"Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2","enrollment":132},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT04295005","phase":"","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":24500},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT06148259","phase":"NA","title":"SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2021-03-12","conditions":"Diabetes Mellitus, Prostatic Hyperplasia","enrollment":57},{"nctId":"NCT05870462","phase":"PHASE4","title":"Semaglutide and Vascular Regeneration","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2023-04-29","conditions":"Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05266404","phase":"PHASE1","title":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)","enrollment":46},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT05353673","phase":"PHASE2","title":"The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-06-01","conditions":"Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia","enrollment":120},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT05032001","phase":"NA","title":"ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT","status":"UNKNOWN","sponsor":"Metabolic Research Unit","startDate":"2021-08-01","conditions":"Abdominal Obesity, Type 2 Diabetes","enrollment":30},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT03845179","phase":"NA","title":"GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2019-05-29","conditions":"Type2 Diabetes","enrollment":12},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT02377388","phase":"PHASE3","title":"DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-02-07","conditions":"Platelet Aggregation During Acute Myocardial Infarction","enrollment":74},{"nctId":"NCT02653131","phase":"PHASE4","title":"The Use of DPP-4 Inhibitors in Short Bowel Syndrome","status":"TERMINATED","sponsor":"Stanley Dudrick's Memorial Hospital","startDate":"2016-01","conditions":"Short Bowel Syndrome","enrollment":8},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT00813228","phase":"PHASE1","title":"Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2009-01-06","conditions":"Diabetes Mellitus Type 1, Diabetes Mellitus Type 2","enrollment":76},{"nctId":"NCT03267576","phase":"PHASE4","title":"An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT03813316","phase":"PHASE4","title":"Approaches To Therapy Escalation In T2D","status":"WITHDRAWN","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2019-05-01","conditions":"Type2 Diabetes","enrollment":""},{"nctId":"NCT04061473","phase":"NA","title":"Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2019-04-02","conditions":"Diabetes After Total Pancreatectomy","enrollment":20},{"nctId":"NCT02330406","phase":"PHASE4","title":"Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial","status":"COMPLETED","sponsor":"Institute for Clinical Effectiveness, Japan","startDate":"2015-04","conditions":"Dipeptidyl-Peptidase 4 Inhibitors, LDL Cholesterol, Glycosylated Hemoglobin","enrollment":353},{"nctId":"NCT03717688","phase":"PHASE4","title":"The Effects of Neprilysin on Glucagon-like Peptide-1","status":"COMPLETED","sponsor":"Nicolai Jacob Wewer Albrechtsen","startDate":"2018-05-17","conditions":"Diabetes, Heart Failure","enrollment":19},{"nctId":"NCT02312063","phase":"PHASE4","title":"Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Kansai Electric Power Hospital","startDate":"2015-02","conditions":"Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT01930188","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1231},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT02333591","phase":"PHASE4","title":"Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults","status":"COMPLETED","sponsor":"Mette Zander","startDate":"2016-07","conditions":"Coronary Microvascular Dysfunction","enrollment":25},{"nctId":"NCT01378117","phase":"PHASE4","title":"Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-08","conditions":"Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia","enrollment":90},{"nctId":"NCT02639637","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Vasoconstriction","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT03602638","phase":"PHASE4","title":"Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2018-10-01","conditions":"Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1","enrollment":300},{"nctId":"NCT02741687","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-06","conditions":"Hyperglycemia","enrollment":80},{"nctId":"NCT00888238","phase":"PHASE1","title":"A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT01847144","phase":"PHASE4","title":"MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":143},{"nctId":"NCT02513771","phase":"PHASE2","title":"Sitagliptin for Reducing Inflammation and Immune Activation","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2015-09","conditions":"HIV-1 Infection","enrollment":90},{"nctId":"NCT02940184","phase":"NA","title":"GLP-1 Signaling in Truncally Vagotomized Subjects","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2016-06","conditions":"Physiology","enrollment":24},{"nctId":"NCT02406443","phase":"PHASE4","title":"The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-03","conditions":"Type 2 Diabetes","enrollment":36},{"nctId":"NCT02312427","phase":"PHASE4","title":"DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Mitsui Memorial Hospital","startDate":"2015-01","conditions":"Heart Failure, Diabetes Mellitus","enrollment":10},{"nctId":"NCT01856907","phase":"PHASE4","title":"Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM","status":"COMPLETED","sponsor":"Woman's","startDate":"2013-09-28","conditions":"Disorder of Glucose Regulation","enrollment":36},{"nctId":"NCT00451113","phase":"PHASE2","title":"Sitagliptin in the Elderly","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT00853944","phase":"PHASE3","title":"Effect of Sitagliptin on Graft Function Following Islet Transplantation","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2009-07","conditions":"Islet Transplantation","enrollment":12},{"nctId":"NCT01155284","phase":"PHASE2","title":"Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanford Health","startDate":"2010-08","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT02192853","phase":"PHASE4","title":"Correlation Between Plasma- and Endothelial DPP-4 Activity","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02089438","phase":"PHASE4","title":"DPP-4 Inhibition, Incretins and Islet Function","status":"COMPLETED","sponsor":"Lund University","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT02048904","phase":"PHASE4","title":"Use of Sitagliptin to Decrease Microalbuminuria","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2014-01","conditions":"Type 2 Diabetes, Microalbuminuria","enrollment":142},{"nctId":"NCT03180281","phase":"NA","title":"Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-07-01","conditions":"Type 2 Diabetes Mellitus","enrollment":135},{"nctId":"NCT01189890","phase":"PHASE3","title":"Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08-16","conditions":"Type 2 Diabetes Mellitus","enrollment":480},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT01610154","phase":"PHASE4","title":"Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics","status":"COMPLETED","sponsor":"Guangwei Li","startDate":"2012-10","conditions":"Insulin Secretion, Insulin Resistance","enrollment":85},{"nctId":"NCT03122041","phase":"PHASE4","title":"Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2016-08","conditions":"PCOS","enrollment":30},{"nctId":"NCT01046110","phase":"PHASE3","title":"Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":458},{"nctId":"NCT01937598","phase":"PHASE3","title":"Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D","status":"COMPLETED","sponsor":"Michael A. Nauck","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT02015910","phase":"PHASE4","title":"Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2014-01","conditions":"Type II Diabetes","enrollment":1},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01859793","phase":"PHASE4","title":"Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2013-06","conditions":"Diabetes, Atherosclerosis","enrollment":38},{"nctId":"NCT02941445","phase":"PHASE4","title":"Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2015-10","conditions":"Polycystic Ovary Syndrome, Body Weight","enrollment":24},{"nctId":"NCT02263677","phase":"PHASE4","title":"Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI","status":"WITHDRAWN","sponsor":"University of Missouri-Columbia","startDate":"2014-03","conditions":"Type 2 Diabetes, Non-alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT01235819","phase":"PHASE4","title":"Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Command Hospital, India","startDate":"2010-11","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT02802644","phase":"PHASE4","title":"The Effect of DPP4 Inhibitor on Vasclular Healing","status":"UNKNOWN","sponsor":"Chung-Ang University","startDate":"2016-06","conditions":"Acute Coronary Syndrome, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT01038648","phase":"PHASE3","title":"Sitagliptin in Prevention of Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2011-12","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01901861","phase":"NA","title":"Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Lund University","startDate":"2013-07","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT01449747","phase":"PHASE4","title":"Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01744236","phase":"PHASE4","title":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT02607410","phase":"PHASE4","title":"Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT01413542","phase":"NA","title":"Pharmacogenetics of Ace Inhibitor-Associated Angioedema","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2011-11","conditions":"Hypertension, Diabetes Type 2","enrollment":44},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":"Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications","enrollment":100},{"nctId":"NCT00964184","phase":"PHASE4","title":"Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population","status":"COMPLETED","sponsor":"Diabetes Foundation, India","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT00676338","phase":"PHASE3","title":"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes Mellitus","enrollment":820},{"nctId":"NCT02386943","phase":"PHASE4","title":"Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-12","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT01137812","phase":"PHASE3","title":"The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-07","conditions":"Diabetes Mellitus, Type 2","enrollment":756},{"nctId":"NCT00411411","phase":"PHASE3","title":"Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2007-02","conditions":"Type 2 Diabetes","enrollment":49},{"nctId":"NCT01767389","phase":"","title":"Glucagon-like Peptide (GLP) Utilization and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":141,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sitagliptin"],"phase":"phase_3","status":"active","brandName":"DPP-4 inhibitor (sitagliptin)","genericName":"DPP-4 inhibitor (sitagliptin)","companyName":"GRADE Study Group","companyId":"grade-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}